key: cord-0682450-xw9h7lpm authors: Huseynova, Roya Arif; A. Bin Mahmoud, Latifa; Huseynov, Oqtay; Almalkey, Mishary; Amer Almotiri, Ameen; Sumaily, Haider Hussein; AbdelRahim, Adli title: A neonate born to an infected COVID‐19 mother was tested positive just 24 hours after its birth date: 2021-02-10 journal: Clin Case Rep DOI: 10.1002/ccr3.3913 sha: 0c81d1dd1f8e5ea240027d5e9e377c3f2c8947ff doc_id: 682450 cord_uid: xw9h7lpm Given the importance of possible vertical transmission, it is essential to study all neonates delivered from COVID‐19 positive mothers to analyze the route of transmission of infection that will optimize the universal testing for SARS‐CoV‐2 and minimize the risk of disease in neonates. The index case mother is a 16-year-old primigravida pregnant woman who presented to the maternal emergency department on June 13th, 2020, at 17:0 due to premature rupture of membrane (PROM) for 8 hours. Her previous medical history was unremarkable of any medical or pregnancy-related illnesses. She was following up on her pregnancy in a private hospital. There was no history of suspected or confirmed individuals with COVID-19 among her family members. The mother was admitted to the prenatal ward for observation and started on intravenous Ceftriaxone because of PROM. Her initial assessment was body temperature 36.5°C, blood pressure 112/66 mm Hg, respiratory rate 20 breaths per minute, heart rate 118 beats per minute, and oxygen saturation 95% in room air. She did not have any upper respiratory symptoms (cough, sneezing, or sputum). Fetal heart monitoring was reassuring between 130 and 140 beats per minute, with no signs of abnormality. Blood tests showed white blood cells count 10.8 x109 cells /L, neutrophil 7.67x109 cells/L, hemoglobin level 10 g/ dl, and platelet count 194 x109 cells /L; coagulation profile (prothrombin time 11.8 s, partial thromboplastin time 28.7s, international normalized ratio1.1; erythrocyte sedimentation rate 6 mm/h, liver function tests: aspartate aminotransferase 22.6 U/L, alanine transaminase 9.8 U/L, and ferritin level was 74.5 ng/ml. At 00:20 on June 14th, 2020, the mother developed chills, felt feverish, cough, and complained of back pain. Her body temperature was 37.8°C. She was given oral paracetamol for fever and screened for infection. Although the possibility of intraamniotic infection (IAI) was raised, it was low-grade fever (<38°C), and other findings supportive IAI like maternal leukocytosis, purulent cervical discharges, or fetal tachycardia were not present. She was continued on intravenous Ceftriaxone. No signs of respiratory distress were observed. Her oxygen saturation level was 98% on room air. Nasopharyngeal swab for COVID-19 was taken to exclude COVID-19 infection at 04:30 the same day. Maternal GBS testing was negative. Placenta histopathology was not sent. At 6:00, her temperature was 37.8°C, as well as mild dry cough and relative tachycardia. Respiratory rate was 20 breaths per minute chest radiography did not reveal any abnormality. Fortunately, at 8:30, her body temperature and tachycardia subsided, and fetal heart monitoring remained reassuring. Since the mother was suspected of having COVID-19, universal surgical masking, and regular prevention measures for COVID-19 were practiced by healthcare workers who attended the delivery room. Following the local infection control guidelines, the delivery took place in the isolation room with no skin-to-skin contact between the mother and her infant. The baby girl was delivered on June 14 at 17:00 via vaginal delivery without any complications. She was immediately separated from the mother and shifted to a single room where initial steps of resuscitation were applied. Apgar scores were 8, 9 and 9 at 1, 5, and 10 minutes, respectively. Physical examination revealed a well-appearing baby. Birth weight was 3070 grams (50th to 90th percentile), length of 52 cm (50th to 90th percentile), and her head circumference of 35 cm (50th percentile). The newborn was admitted to the level-II neonatal intensive care unit (NICU) in an isolation room with a continuous cardiac monitor. Breastfeeding was prevented according to the local policy of infection control for suspected newborn cases for COVID-19. The infant's body temperature was 36.6°C, and her respiratory rate was 50 breaths per minute, with a heart rate of 144 beats per minute. Her oxygen saturation level was greater than 95% on room air. On June 14th, at 20.00, a nasopharyngeal swab result taken from the mother at 04.30 June 14th reported positive for SARS-CoV-2 infection. Nasopharyngeal swab sampling for the baby was taken at the age of 24 hours and also came positive. Her laboratory blood tests showed white blood cells 14.27 x109 cells /L, neutrophil 9.39 x109 cells/L, hemoglobin 17.4 g/dl, platelet 231x109/L, and hematocrit 57%; C-reactive protein 3.11 (positive > 10 mg/L); blood gas analysis pH 7.4 with base excess-5.5; liver function tests: aspartate aminotransferase 16 U/L and alanine transaminase 2.9 U/L. Blood culture was negative. Chest radiography did not reveal any abnormality. The baby continued to be asymptomatic and maintained normal vital signs in room air. She was tolerating regular formula feeding orally. A repeated nasopharyngeal swab done at 48 hours of life was negative. Both baby and mother were discharged home on day 5 with no complication. The baby was monitored until day 28 of life, and she remained asymptomatic. Presently, the possibility of vertical transmission is a big question to neonatologists and obstetricians. Based on most negative samples from vaginal discharge, nasopharyngeal swabs, amniotic fluid, or breast milk, the World Health Organization reports no vertical transmission evidence when COVID-19 infection appears in pregnant women in the last trimester. 4 This conclusion opposed the recently reported paper suggesting vertical transmission on preterm neonate delivered from the COVID-19 positive mother under infection control and prevention measures where testing for reversetranscription polymerase chain reaction (RT-PCR) of | 3 HUSEYNOVA Et Al. bronchoalveolar lavage, rectal swabs, amniotic fluid, blood, and nasopharyngeal swab in a neonate was positive for E and S genes COVID-19 virus. 5 Other reports also identified the presence of SARS-CoV-2 in the villous chorion and amniotic fluid. 6 The index case is a term newborn baby with nasopharyngeal swab sample testing positive by RT-PCR for SARS-CoV-2 infection at 24 hours after vaginal delivery. Although the test's optimal timing is not precise, the Centers for Disease Control and Prevention suggest doing a test at 24 hours of age to avoid the possibility of false-positive results due to contamination of the SARS-CoV-2 that may present in maternal fluids. 7 Our case one of the few reported positive nasopharyngeal swab RT-PCR performed at 24 hours of age. Though the possibility of cross-infection should be considered in the presented case, it was doubtful due to the immediate separation of mother and daughter after birth and applied airborne, droplet, and contact transmission precautions. Delayed cord clamping was not done, and the neonate was kept in an incubator in a single room. The possibility of the intrauterine vertical transmission of SAR -CoV-2 infection was also demonstrated in other reports. 8-12 . Zeng et al presented the report of neonates with positive pharyngeal tests two days after birth. Infants were symptomatic with the pneumonic findings in chest radiography that raised the possibility of vertical transmission of COVID-19. 11 Authors reported positive SARS-CoV-2 with nasopharyngeal and anal swab samples collected on the infants on day 2 of life with strict infection prevention and control during procedures done throughout the delivery. Almost all reported cases were delivered by the emergency cesarean section and had confirmed maternal SARS-CoV-2 infection. Our case was born by vaginal labor, though the risk of cross-infection during vaginal delivery is not clear, while Carosso et al suggest that vaginal delivery is one of the potential risk factors for vertical transmission because of contact with SARS-CoV-2 present in the maternal stool. 13 Furthermore, Scorzolini et al observed a positive pharyngeal PCR test of vaginal fluid in a woman with COVID-19 infection that provides the potential possibility of COVID-19 vertical transmission in vaginal delivery 12 . Interestingly, the authors observed initially negative PCR result of vaginal swab that turned into positive on day 7 and 20 after SARS-CoV-2 symptoms in the pregnant women that advocate cesarean section in case of maternal COVID-19 infection. A recently published report described neonate with positive nasopharyngeal, oropharyngeal swabs immediately after birth, where mother and baby stools were also positive for SARS-CoV-2, besides the viral RNA detected in the breast milk. 14 Although, nasopharyngeal swab specimen for SARS-CoV-2 by RT-PCR is considered one of the best ways to confirm COVID-19; however, most studies did not reveal the presence of SARS-CoV-2 RNA in the specimens like amniotic fluid, cord blood, breast milk, or vaginal secretions. Udugama et al suggest that the results may be influenced by viral load, sample technique, or early disease stage. 15 Those raise concerns about the real validity of a negative pharyngeal swab RT-PCR test in infants born to COVID-19 positive mothers. 16 Therefore, negative RT PCR cannot rule out COVID-19 infection. Moreover, the evidence of vertical transmission of COVID-19 was assessed by Ig M antibodies' level in the infants from COVID-19 mothers in several studies. Dong et al reported elevated IgM antibodies to SARS-CoV-2 two hours after the birth in a neonate born to confirmed SARS-CoV-2 pregnant women. 17 Also, elevated anti-SARS-CoV-2 IgM antibodies were observed in two newborn infants in another recently published study suggesting the intrauterine infection, 18 though, at the same time, several requested nasopharyngeal swabs for COVID-19 were negative in both reports. These serological results raise more concern about the risk of vertical transmission from mother to her baby. However, the rate of false-positive results is significant in serologic studies and a challenging route to approach many congenital infections. Based on the latest update from the Centers for Disease Control and Prevention, at present serologic testing in detecting SARS-CoV-2 acute infection is limited and not recommended. 7 During the whole hospital course, our patient was stable. Several studies in newborn infants with COVID −19, suggesting that infants usually have mild manifestations of the disease. 9, 10, 19 However, several reported clinical analyses proposed that infants with SARS-CoV-2 infection may present with premature delivery, respiratory distress, gastrointestinal symptoms, and laboratory results abnormalities like elevated liver enzymes, thrombocytopenia, and increased mortality rate. 20 We hypothesize that vaginal mode of delivery, PROM, and possible contact with a maternal stool that may contain SARS-CoV-2 may lead to vertical transmission of the virus in the presented case delivered in strict isolation mode with a positive pharyngeal swab at the age of 24 hours. However, our report is limited by the lack of mother's milk, amniotic fluid, and cord blood testing. Our case is a probable case of congenital COVID-19. However, for confirmation of congenital COVID-19, more evidence is required to determine the route of vertical transmission. Variability of testing and findings raised the importance of universal approach protocol for suspected COVID-19 neonates that would allow more optimal methods of diagnosis all over the world. Given the importance of vertical transmission, it is suggested to apply proper infection control and prevention measures, early separation, isolation, and screening neonates delivered from COVID-19 positive mother with further close follow-up. Coronavirus Disease 2019 (COVID-19) and pregnancy: what obstetricians need to know Potential maternal and infant outcomes from coronavirus 2019-nCoV (SARS-CoV-2) infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections COVID19 during pregnancy: a systematic review of reported cases clinical-management-of-severe-acuterespiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected%0A Transplacental transmission of SARS-CoV-2 infection Vertical transmission of COVID-19: SARS-CoV-2 RNA on the fetal side of the placenta in pregnancies with COVID-19 positive mothers and neonates at birth Evaluation and Management Considerations for Neonates at Risk for COVID-19 The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): a Chinese perspective Possible vertical transmission of SARS CoV-2 from an infected mother to her newborn Antibodies in infants born to mothers with COVID-19 pneumonia Coronavirus disease in newborns and very young infants Is SARS-CoV-2 Vertically Transmitted? Front Pediatr A case report of neonatal COVID-19 infection in China Neonatal early-onset infection with SARS-CoV-2 in 33 neonates born to mothers withCOVID-19 in Wuhan A case report of newborn infant with severe COVID-19 in Mexico: Detection of SARS-CoV-2 in Human breast milk and stool Pre-labor anorectal swab for SARS-CoV-2 in COVID-19 pregnant patients: is it time to think about it? Comment of the potential risks of sexual and vertical transmission of Covid-19 infection Diagnosing COVID-19: The disease and tools for detection Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records None to declare. RAH: collected the data, wrote the paper, and critically revised the article. LBM, HHS, and AAR: critically revised the article. OIH, MA, and AAR: collected the data and prepared the primary draft. Informed consent was obtained from parents for reporting this case. The data that support the findings of this study are available on request from the corresponding author on the reasonable request. https://orcid. org/0000-0002-8914-5892 Oqtay Huseynov https://orcid.org/0000-0002-9456-2519